Literature DB >> 21828333

Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure.

Andreas S Barth1, Ami Kumordzie, Constantine Frangakis, Kenneth B Margulies, Thomas P Cappola, Gordon F Tomaselli.   

Abstract

BACKGROUND: Systolic heart failure (HF) is a complex systemic syndrome that can result from a wide variety of clinical conditions and gene mutations. Despite phenotypic similarities, characterized by ventricular dilatation and reduced contractility, the extent of common and divergent gene expression between different forms of HF remains a matter of intense debate. METHODS AND
RESULTS: Using a meta-analysis of 28 experimental (mouse, rat, dog) and human HF microarray studies, we demonstrate that gene expression changes are characterized by a coordinated and reciprocal regulation of major metabolic and signaling pathways. In response to a wide variety of stressors in animal models of HF, including ischemia, pressure overload, tachypacing, chronic isoproterenol infusion, Chagas disease, and transgenic mouse models, major metabolic pathways are invariably downregulated, whereas cell signaling pathways are upregulated. In contrast to this uniform transcriptional pattern that recapitulates a fetal gene expression program in experimental animal models of HF, human HF microarray studies displayed a greater heterogeneity, with some studies even showing upregulation of metabolic and downregulation of signaling pathways in end-stage human hearts. These discrepant results between animal and human studies are due to a number of factors, prominently cardiac disease and variable exposure to cold cardioplegic solution in nonfailing human samples, which can downregulate transcripts involved in oxidative phosphorylation (OXPHOS), thus mimicking gene expression patterns observed in failing samples. Additionally, β-blockers and ACE inhibitor use in end-stage human HF was associated with higher levels of myocardial OXPHOS transcripts, thus partially reversing the fetal gene expression pattern. In human failing samples, downregulation of metabolism was associated with hemodynamic markers of disease severity.
CONCLUSIONS: Irrespective of the etiology, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways. Gene expression changes along this metabolic-signaling axis in mammalian myocardium are a consistent feature in the heterogeneous transcriptional response observed in phenotypically similar models of HF.

Entities:  

Mesh:

Year:  2011        PMID: 21828333      PMCID: PMC3398805          DOI: 10.1161/CIRCGENETICS.110.957571

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  35 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Altered patterns of gene expression in response to myocardial infarction.

Authors:  L W Stanton; L J Garrard; D Damm; B L Garrick; A Lam; A M Kapoun; Q Zheng; A A Protter; G F Schreiner; R T White
Journal:  Circ Res       Date:  2000-05-12       Impact factor: 17.367

Review 3.  A systematic review of large scale and heterogeneous gene array data in heart failure.

Authors:  Umesh C Sharma; Saraswati Pokharel; Chris T A Evelo; Jos G Maessen
Journal:  J Mol Cell Cardiol       Date:  2005-03       Impact factor: 5.000

4.  The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes.

Authors:  R B Vega; J M Huss; D P Kelly
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

5.  Genome-wide expression profiling of a cardiac pressure overload model identifies major metabolic and signaling pathway responses.

Authors:  Roger A Wagner; Raymond Tabibiazar; Jennifer Powers; Daniel Bernstein; Thomas Quertermous
Journal:  J Mol Cell Cardiol       Date:  2004-12       Impact factor: 5.000

6.  Meta-analysis and profiling of cardiac expression modules.

Authors:  Uri David Akavia; Dafna Benayahu
Journal:  Physiol Genomics       Date:  2008-09-09       Impact factor: 3.107

Review 7.  Intrinsically disordered proteins in human diseases: introducing the D2 concept.

Authors:  Vladimir N Uversky; Christopher J Oldfield; A Keith Dunker
Journal:  Annu Rev Biophys       Date:  2008       Impact factor: 12.981

8.  Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation.

Authors:  Sarah Crunkhorn; Farrell Dearie; Christos Mantzoros; Hiral Gami; Wagner S da Silva; Daniel Espinoza; Ryan Faucette; Kristen Barry; Antonio C Bianco; Mary Elizabeth Patti
Journal:  J Biol Chem       Date:  2007-04-06       Impact factor: 5.157

9.  Expression profiling of human idiopathic dilated cardiomyopathy.

Authors:  Rafal Grzeskowiak; Henning Witt; Mario Drungowski; Rolf Thermann; Steffen Hennig; Andreas Perrot; Karl J Osterziel; Dirk Klingbiel; Stefanie Scheid; Rainer Spang; Hans Lehrach; Patricia Ruiz
Journal:  Cardiovasc Res       Date:  2003-08-01       Impact factor: 10.787

10.  Identification of a core set of genes that signifies pathways underlying cardiac hypertrophy.

Authors:  Claes C Strøm; Mogens Kruhøffer; Steen Knudsen; Frank Stensgaard-Hansen; Thomas E N Jonassen; Torben F Orntoft; Stig Haunsø; Søren P Sheikh
Journal:  Comp Funct Genomics       Date:  2004
View more
  32 in total

Review 1.  Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT.

Authors:  Andreas S Barth; Khalid Chakir; David A Kass; Gordon F Tomaselli
Journal:  J Cardiovasc Transl Res       Date:  2012-02-07       Impact factor: 4.132

Review 2.  Metabolic stress in the myocardium: adaptations of gene expression.

Authors:  Peter A Crawford; Jean E Schaffer
Journal:  J Mol Cell Cardiol       Date:  2012-06-21       Impact factor: 5.000

3.  Right ventricular protein expression profile in end-stage heart failure.

Authors:  Yan Ru Su; Manuel Chiusa; Evan Brittain; Anna R Hemnes; Tarek S Absi; Chee Chew Lim; Thomas G Di Salvo
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 4.  Gene scanning and heart attack risk.

Authors:  Andreas S Barth; Gordon F Tomaselli
Journal:  Trends Cardiovasc Med       Date:  2015-07-17       Impact factor: 6.677

5.  Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome.

Authors:  D Kent Arrell; Christian S Rosenow; Satsuki Yamada; Atta Behfar; Andre Terzic
Journal:  NPJ Regen Med       Date:  2020-03-12

6.  Right ventricular long noncoding RNA expression in human heart failure.

Authors:  Thomas G Di Salvo; Yan Guo; Yan Ru Su; Travis Clark; Evan Brittain; Tarek Absi; Simon Maltais; Anna Hemnes
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 7.  Decoding the cardiac message: the 2011 Thomas W. Smith Memorial Lecture.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

8.  Widespread Down-Regulation of Cardiac Mitochondrial and Sarcomeric Genes in Patients With Sepsis.

Authors:  Scot J Matkovich; Belal Al Khiami; Igor R Efimov; Sarah Evans; Justin Vader; Ashwin Jain; Bernard H Brownstein; Richard S Hotchkiss; Douglas L Mann
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

9.  Dynamic gene expression patterns in animal models of early and late heart failure reveal biphasic-bidirectional transcriptional activation of signaling pathways.

Authors:  Janelle Rowell; Norimichi Koitabashi; David A Kass; Andreas S Barth
Journal:  Physiol Genomics       Date:  2014-08-26       Impact factor: 3.107

10.  Dysregulation of cardiolipin biosynthesis in pediatric heart failure.

Authors:  Kathryn C Chatfield; Genevieve C Sparagna; Carmen C Sucharov; Shelley D Miyamoto; Jonathan E Grudis; Rebecca D Sobus; Jamie Hijmans; Brian L Stauffer
Journal:  J Mol Cell Cardiol       Date:  2014-06-14       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.